ecrin-mdr-crcClinical2008Colorectal cancer metastaticSegunda linea de tratamiento en pacientes con carcinoma colorectal. Second line treatment of patients with metastatic carcinoma of colon and rectumSegunda linea de tratamiento en pacientes con carcinoma colorectal.Second line treatment of patients with metastatic carcinoma of colon and rectumColorectal NeoplasmsMetastatic colorectal cancerMetastatic Colorectal CancerSegunda Linea De Tratamiento En Pacientes Con Carcinoma Colorectal.second Line Treatment Of Patients With Metastatic Carcinoma Of Colon And RectumColorectal NeoplasmsColorectal Cancer MetastaticSegunda Linea De Tratamiento En Pacientes Con Carcinoma Colorectal. second Line Treatment Of Patients With Metastatic Carcinoma Of Colon And RectumInterventionalhttps://newmdr.ecrin.org/Study/2050615CanadaSouth KoreaBelgiumUnited StatesCzechiaJapanPolandItalyFranceSpain3IrinotecanOxaliplatinLevoleucovorinAxitinibLeucovorinAcido FolinicoFluorouracilBevacizumabECRIN MDRCompletedfalseA Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line RegimenThe study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients with metastatic colorectal cancer after failure of an irinotecan or oxaliplatin-containing first-line regimen.2008-03-152050615NCT006150562007-006283-30